Back to top
more

Alimera Sciences (ALIM)

(Delayed Data from NSDQ)

$3.34 USD

3.34
48,043

-0.10 (-2.91%)

Updated Apr 19, 2024 04:00 PM ET

After-Market: $3.46 +0.12 (3.59%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

New Strong Sell Stocks for March 13th

by Zacks Equity Research

ASLE, ALIM and CADE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2024.

Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -450% and 4.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Novavax (NVAX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Novavax (NVAX) delivered earnings and revenue surprises of -193.88% and 12.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 85.37% and 4.25%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -833.33% and 13.86%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Medical Stocks Lagging 89BIO (ETNB) This Year?

by Zacks Equity Research

Here is how 89BIO (ETNB) and Alimera Sciences (ALIM) have performed compared to their sector so far this year.

Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum

by Zacks Equity Research

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Alimera Sciences (ALIM) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?

by Zacks Equity Research

Here is how Alimera Sciences (ALIM) and Haemonetics (HAE) have performed compared to their sector so far this year.

Alimera (ALIM) Completes Enrollment in Eye Disease Study

by Zacks Equity Research

Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.

Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock

by Zacks Equity Research

Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq

by Zacks Equity Research

Alimera's (ALIM) stock jumps 19.4% after the company inks a deal with Eyepoint to acquire additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq

Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -22.41% and 4.20%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of 28.57% and 15.30%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ChromaDex (CDXC) delivered earnings and revenue surprises of 40% and 16.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 7.50% and 5.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Alimera Sciences (ALIM) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -92.86% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biohaven Ltd. (BHVN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Biohaven Ltd. (BHVN) delivered earnings and revenue surprises of 30.83% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Mersana Therapeutics, Inc. (MRSN) delivered earnings and revenue surprises of -1,933.33% and 85.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Lags Q3 Earnings Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of -16.78% and 1.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to their sector so far this year.